Phil Graham

Phil is the Chief Development Officer. He has over 30 years of experience in the pharmaceutical industry, working in a variety of drug development roles at Eli Lilly, Metasyn, EPIX Pharmaceuticals, Concert Pharmaceuticals and Sojournix. At Metasyn and EPIX, Phil held line management roles including pharmacology, toxicology, (bio)analytical, and manufacturing for support of two clinical-stage imaging programs. In addition, he also served as overall project leader for gadofosveset during late-stage development and regulatory review culminating in approvals in Europe (2005), and the US (2008). After the acquisition of Predix Pharmaceuticals by EPIX, he served as project leader for clinical programs in pulmonary hypertension and Alzheimer’s Disease, both of which advanced through proof-of-concept studies in patients. At Concert, Phil held leadership roles for programs in a variety of indications as well as assessing development strategies for several deuterated molecules. Phil served as Chief Development Officer at Sojournix with various operational and strategic responsibilities.

Phil has a PhD in analytical and physical chemistry from the University of Massachusetts, Amherst and a BS (Hons, 1st class) from the University of Otago, New Zealand.